FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2320549610> ?p ?o ?g. }

• W2320549610 endingPage "3292" @default.
• W2320549610 startingPage "3287" @default.
• W2320549610 abstract "Ovarian cancer is a clinical type of gynecological malignant tumor with poor prognosis and a high mortality rate. At present, the primary treatment method used is surgery, with chemotherapy as an ajdunctive therapy. Thus, new short-term treatments should be identified. The aim of the present study was to investigate the short-term curative effects and safety of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. A total of 112 cases of advanced (stage III-IV) ovarian cancer patients confirmed by clinical diagnosis between October 2014 and December 2015 were included in the study. The patients were randomly divided into the study and control groups (n=56 cases). The control group was treated with docetaxel and intraperitoneal cisplatin hyperthermic perfusion chemotherapy, while the study group was treated with docetaxel venous chemotherapy and intraperitoneal cisplatin cyclical hyperthermic perfusion chemotherapy with BR-TRG-1 body cavity hyperthermic perfusion treatment system. Clinical treatment results for short-term curative effects and adverse reactions were compared and analyzed 8 weeks after treatment. The total effective rate of the study and control groups were 87.5 and 62.5%, respectively, and the difference was statistically significant (P<0.05). The controlled rate of ascites, remission rate of tumor and descent rate of CA125 of patients in the study group were better than patients in the control group (P<0.05). The rate of adverse reactions of patients in the study group was 39.3%, and the grade of toxicity was from I to II, while the rate of adverse reactions of patients in the control group was 55.4%, and the grade of toxicity was from II to III. The difference between the two groups was statistically significant (P<0.05). In conclusion, applying the combination of docetaxel, intraperitoneal cisplatin hyperthermic perfusion chemotherapy and hyperthermia to treat advanced ovarian cancer can improve the curative effects with little toxicity; thus, it is worthy of promotion and application." @default.
• W2320549610 created "2016-06-24" @default.
• W2320549610 creator A5003668456 @default.
• W2320549610 creator A5008813265 @default.
• W2320549610 creator A5051735325 @default.
• W2320549610 creator A5053862338 @default.
• W2320549610 creator A5088617130 @default.
• W2320549610 date "2016-04-05" @default.
• W2320549610 modified "2023-10-17" @default.
• W2320549610 title "Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer" @default.
• W2320549610 cites W1578654420 @default.
• W2320549610 cites W1976191662 @default.
• W2320549610 cites W1976986479 @default.
• W2320549610 cites W1986681839 @default.
• W2320549610 cites W1991023289 @default.
• W2320549610 cites W2014525460 @default.
• W2320549610 cites W2022462471 @default.
• W2320549610 cites W2022783785 @default.
• W2320549610 cites W2031310862 @default.
• W2320549610 cites W2036832628 @default.
• W2320549610 cites W2038144751 @default.
• W2320549610 cites W2051964522 @default.
• W2320549610 cites W2053510750 @default.
• W2320549610 cites W2056931418 @default.
• W2320549610 cites W2065791944 @default.
• W2320549610 cites W2068244356 @default.
• W2320549610 cites W2072060792 @default.
• W2320549610 cites W2080407657 @default.
• W2320549610 cites W2107037361 @default.
• W2320549610 cites W2112625834 @default.
• W2320549610 cites W2133778309 @default.
• W2320549610 cites W2151456396 @default.
• W2320549610 cites W403663872 @default.
• W2320549610 doi "https://doi.org/10.3892/ol.2016.4414" @default.
• W2320549610 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4840847" @default.
• W2320549610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27123104" @default.
• W2320549610 hasPublicationYear "2016" @default.
• W2320549610 type Work @default.
• W2320549610 sameAs 2320549610 @default.
• W2320549610 citedByCount "11" @default.
• W2320549610 countsByYear W23205496102016 @default.
• W2320549610 countsByYear W23205496102017 @default.
• W2320549610 countsByYear W23205496102019 @default.
• W2320549610 countsByYear W23205496102021 @default.
• W2320549610 countsByYear W23205496102022 @default.
• W2320549610 countsByYear W23205496102023 @default.
• W2320549610 crossrefType "journal-article" @default.
• W2320549610 hasAuthorship W2320549610A5003668456 @default.
• W2320549610 hasAuthorship W2320549610A5008813265 @default.
• W2320549610 hasAuthorship W2320549610A5051735325 @default.
• W2320549610 hasAuthorship W2320549610A5053862338 @default.
• W2320549610 hasAuthorship W2320549610A5088617130 @default.
• W2320549610 hasBestOaLocation W23205496101 @default.
• W2320549610 hasConcept C121608353 @default.
• W2320549610 hasConcept C126322002 @default.
• W2320549610 hasConcept C126894567 @default.
• W2320549610 hasConcept C141071460 @default.
• W2320549610 hasConcept C143998085 @default.
• W2320549610 hasConcept C146957229 @default.
• W2320549610 hasConcept C197934379 @default.
• W2320549610 hasConcept C2776283816 @default.
• W2320549610 hasConcept C2776694085 @default.
• W2320549610 hasConcept C2778239845 @default.
• W2320549610 hasConcept C2779949491 @default.
• W2320549610 hasConcept C2780427987 @default.
• W2320549610 hasConcept C2780496750 @default.
• W2320549610 hasConcept C2781190966 @default.
• W2320549610 hasConcept C2781451048 @default.
• W2320549610 hasConcept C71924100 @default.
• W2320549610 hasConcept C90924648 @default.
• W2320549610 hasConceptScore W2320549610C121608353 @default.
• W2320549610 hasConceptScore W2320549610C126322002 @default.
• W2320549610 hasConceptScore W2320549610C126894567 @default.
• W2320549610 hasConceptScore W2320549610C141071460 @default.
• W2320549610 hasConceptScore W2320549610C143998085 @default.
• W2320549610 hasConceptScore W2320549610C146957229 @default.
• W2320549610 hasConceptScore W2320549610C197934379 @default.
• W2320549610 hasConceptScore W2320549610C2776283816 @default.
• W2320549610 hasConceptScore W2320549610C2776694085 @default.
• W2320549610 hasConceptScore W2320549610C2778239845 @default.
• W2320549610 hasConceptScore W2320549610C2779949491 @default.
• W2320549610 hasConceptScore W2320549610C2780427987 @default.
• W2320549610 hasConceptScore W2320549610C2780496750 @default.
• W2320549610 hasConceptScore W2320549610C2781190966 @default.
• W2320549610 hasConceptScore W2320549610C2781451048 @default.
• W2320549610 hasConceptScore W2320549610C71924100 @default.
• W2320549610 hasConceptScore W2320549610C90924648 @default.
• W2320549610 hasIssue "5" @default.
• W2320549610 hasLocation W23205496101 @default.
• W2320549610 hasLocation W23205496102 @default.
• W2320549610 hasLocation W23205496103 @default.
• W2320549610 hasLocation W23205496104 @default.
• W2320549610 hasOpenAccess W2320549610 @default.
• W2320549610 hasPrimaryLocation W23205496101 @default.
• W2320549610 hasRelatedWork W1967786039 @default.
• W2320549610 hasRelatedWork W1982849070 @default.
• W2320549610 hasRelatedWork W2027569686 @default.
• W2320549610 hasRelatedWork W2061934283 @default.

• next